- Home
- EPSN vs IPHA Comparison
EPSN vs IPHA Comparison
Compare EPSN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- IPHA
- Stock Information
- Founded
- EPSN 2005
- IPHA 1999
- Country
- EPSN Canada
- IPHA France
- Employees
- EPSN N/A
- IPHA N/A
- Industry
- EPSN Oil & Gas Production
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- EPSN Energy
- IPHA Health Care
- Exchange
- EPSN Nasdaq
- IPHA Nasdaq
- Market Cap
- EPSN 153.4M
- IPHA 160.1M
- IPO Year
- EPSN N/A
- IPHA 2019
- Fundamental
- Price
- EPSN $6.59
- IPHA $2.38
- Analyst Decision
- EPSN Strong Buy
- IPHA Strong Buy
- Analyst Count
- EPSN 1
- IPHA 1
- Target Price
- EPSN $7.00
- IPHA $11.00
- AVG Volume (30 Days)
- EPSN 45.7K
- IPHA 31.8K
- Earning Date
- EPSN 05-14-2025
- IPHA 03-27-2025
- Dividend Yield
- EPSN 3.73%
- IPHA N/A
- EPS Growth
- EPSN N/A
- IPHA N/A
- EPS
- EPSN 0.09
- IPHA N/A
- Revenue
- EPSN $31,522,775.00
- IPHA $20,831,349.00
- Revenue This Year
- EPSN $41.35
- IPHA $209.83
- Revenue Next Year
- EPSN N/A
- IPHA $83.96
- P/E Ratio
- EPSN $73.15
- IPHA N/A
- Revenue Growth
- EPSN 2.58
- IPHA N/A
- 52 Week Low
- EPSN $4.95
- IPHA $1.29
- 52 Week High
- EPSN $7.32
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- EPSN 45.40
- IPHA 71.42
- Support Level
- EPSN $6.33
- IPHA $2.13
- Resistance Level
- EPSN $7.28
- IPHA $2.34
- Average True Range (ATR)
- EPSN 0.30
- IPHA 0.14
- MACD
- EPSN -0.05
- IPHA 0.04
- Stochastic Oscillator
- EPSN 27.08
- IPHA 90.07
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.